Upsurge of respiratory illnesses reported among children in Northern China
On Nov. 23, 2023, the World Health Organization (WHO) announced that it was monitoring data from Chinese surveillance…
U.S. FDA approved treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene
On Apr. 25, 2023, the U.S. FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS)…
University of Wisconsin and TGen researchers used machine learning to make early detection of cancerm more accessible
On Jan. 13, 2023, a team of researchers including faculty at the Translational Genomics Research Institute (TGen), part…
Published study detailed proof-of-concept for COVID-19 detection via saliva screening
On Feb. 23, 2022, Agilent Technologies announced that researchers at the Indian Institute of Technology Bombay in India…
WHO advised against use of convalescent plasma for covid-19
On Dec. 6, 2021, the World Health Organization Guideline Development Group of international experts announced in the BMJ…
EUROIMMUN anti-SARS-CoV-2 S1 curve ELISA received FDA Emergency Use Authorization
On Oct. 5, 2021, PerkinElmer announced that the U.S. Food and Drug Administration had provided Emergency Use Authorization…
Researchers developed COVID-19 severity screening method based on the Agilent Cary 630 FTIR spectrometer
On Aug. 18, 2021, Agilent Technologies announced that researchers at the Indian Institute of Technology Bombay in India…
clinical trial tested donated antibodies for effectiveness in fighting infection caused by Coronavirus
On Aug. 19, 2021, Oregon Health & Science University (OHSU) announced that it was part of a randomized,…
NIH study showed no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms
On Aug. 18, 2021, the final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO)…
ADMA Biologics received FDA approval for plasma collection facility in Maryville, TN
On Aug. 16, 2021, ADMA Biologics announced that it had received U.S. Food and Drug Administration approval for…
NIH halted trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms
On Mar. 2, 2021, the NIH halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent…
Agilent announced immunoassay kit to detect SARS-CoV-2 antibodies
On Feb. 18, 2021, Agilent Technologies announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay…
RECOVERY trial closed recruitment to convalescent plasma treatment for patients hospitalised with COVID-19
On Jan. 15, 2021, Oxford University announced that on advice of the independent Data Monitoring Committee (DMC), recruitment…
Abbott announced fulfillment of Federal government purchase of 150 million BinaxNOWï¾™ COVID-19 Rapid Tests
On Jan. 12, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
Abbott received CE Mark for its COVID-19 IgG quantitative antibody blood test
On Jan. 11, 2021, Abbott announced it had received FDA 510(k) clearance for the first rapid handheld traumatic…
ACON Laboratories received Emergency Use Authorization for its SARS-COV-2 IgG/IgM rapid test
On Dec. 17, 2020, ACON Laboratories announced that its SARS-COV-2 IgG/IgM Rapid Test has been authorized for emergency…
Bio-Techne announced commercial release of SARS-CoV-2 multi-antigen serology assay kit for simple western
On Oct. 19, 2020, Bio-Techne announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for…
Emergent BioSolutionsï¾’ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
NIH expanded clinical trials to test convalescent plasma against COVID-19
On Sept. 22, 2020, the NIH annunced that two randomized, placebo-controlled clinical trials expanded enrollment to further evaluate…
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
ADMA Biologics launched COVID-19 ImmunoRank Neutralization MICRO-ELISA for detection of SARS-CoV-2
On Sept. 3, 2020, ADMA Biologics announced the launch of COVID-19 ImmunoRank Neutralization MICRO-ELISA, a proprietary, fully-validated ELISA…
The US Dept of Veterans Affairs anounced new clinical trial for Veterans with COVID-19
On Aug. 28, 2020, the U.S. Dept. of Veterans Affairs (VA) announced a new clinical trial to study…
XBiotech announced COVID-19 candidate therapy
On Aug. 24, 2020, XBiotech announced that the FDA issued an emergency use authorization (EUA) for COVID-19 Convalescent…
Mayo Clinic discontinued enrollment in Expanded Access Program for convalescent plasma with FDA Emergency Use Authorization
On Aug. 23, 2020, the Mayo Clinic announced that with the FDA Emergency Use Authorization of convalescent plasma,…
FDA issued Emergency Use Authorization for convalescent plasma as potential promising COVIDï¾–19 treatment
On Aug. 23, 2020, the FDA issued an emergency use authorization (EUA) for investigational convalescent plasma for the…
NIH delivered $43 million to support convalescent plasma clinical trial
On Aug. 18, 2020, the National Institutes of Health awarded Albert Einstein College of Medicine and Montefiore a…
Costa Rica announced horse antibodies for trials as an inexpensive COVID-19 therapy
On Aug. 17, 2020, Scientisfic American reported that Costa Rican scientists at the Clodomiro Picado Institute have inoculated…
LabCorp to perform antibody test at no charge to accelerate COVID-19 blood plasma donation
On Aug. 11, 2020, LabCorpï¾® announced details of a no charge antibody testing program in response to federal…
AXIM Biotechnologies applied for FDA Emergency Use Approval for high throughput, neutralizing antibody diagnostic test for COVID-19
On Aug. 5, 2020, AXIM Biotechnologies announced the development, patent filing and Emergency Use Approval (EUA) filing of…
BioAegis received approval to proceed with phase 2 trial of its gelsolin COVID-19 treatment
On Jul. 15, 2020, BioAegis Therapeutics announced that it received regulatory clearance from The Spanish Agency for Medicines…